- Home
- PHUN vs ACET Comparison
PHUN vs ACET Comparison
Compare PHUN & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- ACET
- Stock Information
- Founded
- PHUN 2009
- ACET 1947
- Country
- PHUN United States
- ACET United States
- Employees
- PHUN N/A
- ACET N/A
- Industry
- PHUN EDP Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- ACET Health Care
- Exchange
- PHUN Nasdaq
- ACET Nasdaq
- Market Cap
- PHUN 62.1M
- ACET 70.3M
- IPO Year
- PHUN N/A
- ACET N/A
- Fundamental
- Price
- PHUN $3.00
- ACET $0.74
- Analyst Decision
- PHUN Buy
- ACET Buy
- Analyst Count
- PHUN 2
- ACET 6
- Target Price
- PHUN $8.00
- ACET $6.00
- AVG Volume (30 Days)
- PHUN 337.6K
- ACET 316.1K
- Earning Date
- PHUN 05-08-2025
- ACET 03-06-2025
- Dividend Yield
- PHUN N/A
- ACET N/A
- EPS Growth
- PHUN N/A
- ACET N/A
- EPS
- PHUN N/A
- ACET N/A
- Revenue
- PHUN $3,189,000.00
- ACET N/A
- Revenue This Year
- PHUN $98.49
- ACET N/A
- Revenue Next Year
- PHUN N/A
- ACET N/A
- P/E Ratio
- PHUN N/A
- ACET N/A
- Revenue Growth
- PHUN N/A
- ACET N/A
- 52 Week Low
- PHUN $2.70
- ACET $0.73
- 52 Week High
- PHUN $14.60
- ACET $2.40
- Technical
- Relative Strength Index (RSI)
- PHUN 44.70
- ACET 38.23
- Support Level
- PHUN $2.82
- ACET $0.74
- Resistance Level
- PHUN $3.54
- ACET $0.91
- Average True Range (ATR)
- PHUN 0.18
- ACET 0.06
- MACD
- PHUN 0.05
- ACET -0.00
- Stochastic Oscillator
- PHUN 32.50
- ACET 0.00
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.